Genetic medicines company Modalis Therapeutics Corporation (Tokyo Stock Exchange: 4883) announced on Monday that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease (RPD) designation to MDL-101, a novel treatment for congenital muscular dystrophy type 1a (LAMA2-CMD).
This designation applies to serious diseases affecting children under 18, with fewer than 200,000 cases in the US. Should MDL-101 receive marketing approval, Modalis may obtain a Priority Review Voucher (PRV) for expedited FDA review of another product.
LAMA2-CMD is a severe genetic disorder caused by the absence of the LAMA2 protein, which poses challenges for conventional gene therapy development. Modalis' proprietary CRISPR-GNDM technology enables precise modulation of gene expression without DNA breaks. MDL-101 aims to compensate for LAMA2 deficiency by inducing expression of the sister gene, LAMA1, in muscle tissues, potentially providing a one-time, durable treatment.
Modalis is also pursuing an Orphan Drug application for MDL-101, currently under FDA review. The company's mission is to deliver life-changing treatments for rare genetic diseases.
Johnson & Johnson seeks approval for DARZALEX FASPRO in smoldering multiple myeloma
FDA Panel supports IceCure's ProSense Cryoablation for early-stage breast cancer
Dizal submits NDA to US FDA for sunvozertinib in treating NSCLC with EGFR exon 20 mutations
Naitive Technologies enters strategic agreement with Parvizi Surgical Innovation
Akura Medical's application for trial of Katana Thrombectomy System receives US FDA approval
FDA accepts Ionis Pharmaceuticals' donidalorsen New Drug Application
Kazia Therapeutics secures FDA meeting to explore paxalisib pathways for glioblastoma
Boston Scientific to acquire Cortex Inc in strategic expansion of electrophysiology portfolio
Formosa Pharmaceuticals signs licensing agreement with DÁVI Farmaceutica
Amphix Bio receives USD1m SBIR Phase II grant from National Science Foundation